SCHEMBL5215889

SCHEMBL5215889

CCOC(=O)c1cccc(-n2cc(-c3cnc4ccccc4n3)cn2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.58
RAB9A P51151 9/20 0.58
MAPT P10636 8/20 0.51
KMT2A Q03164 7/20 0.51
MEN1 O00255 6/20 0.51
ALDH1A1 P00352 5/20 0.51
ABCB1 P08183 1/20 0.51
HTT P42858 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
ALOX15 P16050 1/20 0.49
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
KDM4E B2RXH2 2/20 0.48
NPSR1 Q6W5P4 1/20 0.47
ESRRA P11474 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217843 0.85 NPC1 (0.60) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL182208 0.84 KMT2A (0.55) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL27091230 0.82 ACSS2 (0.44) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5218915 0.81 CCNC (0.44) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5216868 0.80 ALOX15 (0.48) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5216692 0.77 MKNK1 (0.57) NPC1RAB9AMAPTALDH1A1
SCHEMBL8353703 0.77 BCHE (0.51) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5217224 0.77 MKNK1 (0.52) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5218811 0.76 RAB9A (0.68) NPC1RAB9AMAPTKMT2AMEN1
SCHEMBL5216715 0.75 ALDH1A1 (0.48) NPC1RAB9AMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885RAB9A 1352/4885MAPT 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.